Publications

In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. by Flamm RK, Rhomberg PR, Huband MD and Farrell DJ published in Antimicrob. Agents Chemother. 2016; 60 (10): 6381-6385

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. by Flamm RK, Rhomberg PR, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 66-69

Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). by Flamm RK, Castanheira M, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2016; 85 (3): 352-355

Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). by Duncan LR, Smart JI, Flamm RK, Sader HS, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 300-302

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the USA (2013-2014). by Duncan LR, Sader HS, Flamm RK, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 303-306

In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. by Flamm RK, Nichols WW, Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents. 2016; 47 (3): 235-242

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. by Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M and Yamano Y published in J. Antimicrob. Chemother. 2016; 71 (3): 670-677

In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study. by Armstrong ES, Farrell DJ, Palchak M and Steenbergen JN published in Antimicrob. Agents. Chemother. 2016; 60 (1): 666-668

In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from United States medical centers by Census region (2014). by Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN and Sader HS. published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2537-2541

In Vitro Activity of Delafloxacin Tested Against Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis, Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Lefamulin, an Pleuromutilin Derivative, against S. aureus Strains with Decreased Susceptibility to Vancomycin, Lead author: Sader HS, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Solithromycin MIC and Disk Diffusion Quality Control Ranges, a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Ross JE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Performance of BD MAX™ StaphSR against S. aureus Clinical Isolates from the 9 USA Census Regions, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design, Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU, Lead author: Jones RN, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial against Neisseria gonorrhoeae. by Riedel S, Ross JE, Farrell DJ, Flamm RK and Jones RN published in J. Clin. Microbiol.: 2015; 53 (12): 3888-3890

In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. by Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF and Bradford PA published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6053-6063

In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. by Flamm RK, Rhomberg PR, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (4): 2280-2285

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3263-3270

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. by Pfaller MA, Rhomberg PR, Messer SA and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 259-263

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2015; 59 (4): 2454-2457

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 275-279

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. by Jones RN, Turnidge JD, Moeck G, Arhin FF and Mendes RE published in Antimicrob. Agents Chemother. 2015; 59 (4): 2405-2409,

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629

In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. by Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1751-1754

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria. by Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF and Mueller JP published in Antimicrob. Agents Chemother. 2015; 59 (1): 467-474

Surrogate Analysis of Vancomycin to Predict Susceptible Categorization of Dalbavancin, Lead author: Jones RN, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Update on Acinetobacter species: Mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options. by Castanheira M, Mendes RE and Jones RN published in Clin. Infect. Dis. 2014; 59 (Suppl 6): S367-373

Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. by Mendes RE, Deshpande LM and Jones RN published in Drug Resist. Updat. 2014; 17 (1-2): 1-12

Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011 – 2012): Ceftaroline remains active in vitro among beta-lactam agents. by Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (8): 4923-4927

In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. by Fernandez-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Florl C and Guarro J published in Antimicrob. Agents Chemother. 2014; 58 (7): 3646-3649

In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). by Flamm RK, Jones RN and Sader HS published in J. Global Antimicrob. Res. 2014; 2 (2): 183-189

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. by Kohlhoff SA, Huband MD and Hammerschlag MR published in Antimicrob. Agents Chemother. 2014; 58 (12): 7595-7596

In vitro activity of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. by Pfaller MA, Messer SA, Rhomberg PR, Jones RN and Castanheira M published in J. Clin. Microbiol. 2013; 51 (8): 2608-2616

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. by VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG. published in Antimicrob. Agents Chemother. 2013; 57 (6): 2809-2814

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in Antimicrob. Agents Chemother. 2013; 57 (2): 1065-1068

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. by He W, Kaniga K, Lynch AS, Flamm RK and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 417-419

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). by Farrell DJ, Castanheira M, Mendes RE, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S206-S214

In vitro activity of a novel broad-spectrum antifungal, E1210, and comparators against Aspergillus spp. as determined by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Castanheira M, Messer SA and Jones RN published in Antimicrob. Agents Chemother. 2011; 55 (11): 5155-5158

In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) Gram-positive organisms collected in the United States. by Jones RN, Mendes RE, Sader HS and Castanheira M published in Clin. Infect. Dis. 2011; 52 (Suppl 7): S477-S486

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. by Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2011; 71 (2): 167-170

JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. by Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN published in Antimcrob. Agents Chemother. 2011; 55 (7): 3631-3634

In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. by Farrell DJ, Krause KM and Benton BM published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 257-279

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler’s diarrhea and Clostridium difficile. by Farrrell DJ, Putnam SD Biedenbach DJ, Moro L, Bozzella R, Celasco G and Jones RN published in Antimicrob. Agents Chemother. 2011; 55 (3): 992-996

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). by Farrell DJ, Castanheira M, Sader HS and Jones RN published in J. Infect. 2010; 61 (6): 476-483

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. by Farrell DJ, Robbins M, Ryhs-Williams W and Love WG published in Int. J. Antimicrob. Agents 2010; 35 (6): 531-536

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. by Biedenbach DJ, Ross JE, Putnam SD and Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (5): 2273-2275